Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma

被引：24
作者：
Nastoupil, Loretta J. [1 ,3 ]
Bartlett, Nancy L. [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Washington Univ, Siteman Canc Ctr, St Louis, MO USA
[3] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 429, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 04期
关键词：
RITUXIMAB PLUS CYCLOPHOSPHAMIDE; PREVIOUSLY UNTREATED PATIENTS; SOUTHWEST-ONCOLOGY-GROUP; NON-HODGKIN-LYMPHOMA; DOUBLE-HIT LYMPHOMA; SINGLE-ARM; OPEN-LABEL; ELDERLY-PATIENTS; PHASE-III; R-CHOP;
D O I：
10.1200/JCO.22.01848
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases. Several recent advances have affected the treatment landscape, which had been mostly stagnant for the past few decades. We will review the practice-changing studies in frontline (POLARIX), early relapse (ZUMA-7 and TRANSFORM), and multiple recurrent (ZUMA-1, JULIET, TRANSCEND, L-MIND, and LOTIS-2) stages and discuss how the treatment landscape may evolve with the emergence of bispecific antibodies.
引用
收藏
页码：903 / +
页数：12
相关论文
共 50 条
  • [41] Mechanism and Treatment of Rituximab Resistance in Diffuse Large B-cell Lymphoma
    Zou, Linqing
    Song, Guoqi
    Gu, Siyu
    Kong, Lingling
    Sun, Shiqi
    Yang, Li
    Cho, William C.
    CURRENT CANCER DRUG TARGETS, 2019, 19 (09) : 681 - 687
  • [42] Recent advances in the understanding and treatment of diffuse large B-cell lymphoma
    Gergely Lajos
    Illes Arpad
    ORVOSI HETILAP, 2016, 157 (31) : 1232 - 1241
  • [43] Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma
    Goldfinger, Mendel
    Xu, Mina
    Bertino, Joseph R.
    Cooper, Dennis L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (06) : E307 - E311
  • [44] Limited-stage diffuse large B-cell lymphoma
    Hawkes, Eliza A.
    Barraclough, Allison
    Sehn, Laurie H.
    BLOOD, 2022, 139 (06) : 822 - 834
  • [45] Prognostication of diffuse large B-cell lymphoma in the rituximab era
    Ninan, Mary J.
    Wadhwa, Punit D.
    Gupta, Pankaj
    LEUKEMIA & LYMPHOMA, 2011, 52 (03) : 360 - 373
  • [46] Current therapeutic strategies for diffuse large B-cell lymphoma
    Pfreundschuh, M.
    INTERNIST, 2016, 57 (03): : 214 - +
  • [47] Second-line treatment of diffuse large B-cell lymphoma: Evolution of options
    Fabbri, N.
    Mussetti, A.
    Sureda, A.
    SEMINARS IN HEMATOLOGY, 2023, 60 (05) : 305 - 312
  • [48] Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance
    Bock, Allison M.
    Wenzl, Kerstin
    Novak, Joseph P.
    Stokes, Matthew E.
    Hopper, Melissa A.
    Krull, Jordan E.
    Dropik, Abigail R.
    Sarangi, Vivek
    Ortiz, Maria
    Stong, Nicholas
    Huang, C. Chris
    Maurer, Matthew J.
    King, Rebecca L.
    Farooq, Umar
    Wang, Yucai
    Witzig, Thomas E.
    Ansell, Stephen M.
    Habermann, Thomas M.
    Cerhan, James R.
    Gandhi, Anita K.
    Nowakowski, Grzegorz
    Novak, Anne J.
    HEMATOLOGICAL ONCOLOGY, 2025, 43 (01)
  • [49] Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?
    Di Rocco, Alice
    De Angelis, Federico
    Ansuinelli, Michela
    Foa, Robin
    Martelli, Maurizio
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (09) : 761 - 774
  • [50] Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?
    Ghione, Paola
    Salles, Gilles
    HAEMATOLOGICA, 2024, 109 (09) : 2802 - 2809
12345